03:50 PM EDT, 07/31/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our target at $232, 16.6x our 2026 EPS estimate, above AbbVie's ( ABBV ) historical forward P/E average, justified by its improving outlook. We adjust our 2025 EPS forecast to $12.08 from $12.34 and keep our 2026 EPS view at $14.01. AbbVie ( ABBV ) delivered another robust set of results in Q2, while continuing to successfully advance its pipeline, in our view. Q2 revenue grew 6.6% Y/Y to $15.4B, driven primarily by the exceptional performance of AbbVie's ( ABBV ) immunology franchise, which generated $7.6B in sales, representing a 9.5% Y/Y increase. Skyrizi led this growth with $4.4B in Q2 sales (+62.2% Y/Y) and Rinvoq contributed $2B (+41.8% Y/Y). Biosimilar competition continued to impact AbbVie's ( ABBV ) key drug Humira's performance with revenues down 58.1% Y/Y to $1.2B in Q2, consistent with expectations, but AbbVie's ( ABBV ) new drugs show promise. In our view, the company's strategic transition away from Humira dependence remains on track, with Skyrizi and Rinvoq demonstrating remarkable growth momentum, which we expect to continue.